DK0741577T3 - Anvendelsen af enterferon, subtype alfa 8, til fremstilling af lægemidler til behandling af virusinfektioner i leveren - Google Patents

Anvendelsen af enterferon, subtype alfa 8, til fremstilling af lægemidler til behandling af virusinfektioner i leveren

Info

Publication number
DK0741577T3
DK0741577T3 DK95910629T DK95910629T DK0741577T3 DK 0741577 T3 DK0741577 T3 DK 0741577T3 DK 95910629 T DK95910629 T DK 95910629T DK 95910629 T DK95910629 T DK 95910629T DK 0741577 T3 DK0741577 T3 DK 0741577T3
Authority
DK
Denmark
Prior art keywords
alpha
ifn
pct
liver
enterferon
Prior art date
Application number
DK95910629T
Other languages
Danish (da)
English (en)
Inventor
Graham Russell Foster
Howard Christopher Thomas
Original Assignee
Imperial College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9404379A external-priority patent/GB9404379D0/en
Priority claimed from GB9420340A external-priority patent/GB9420340D0/en
Application filed by Imperial College filed Critical Imperial College
Application granted granted Critical
Publication of DK0741577T3 publication Critical patent/DK0741577T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK95910629T 1994-03-07 1995-03-07 Anvendelsen af enterferon, subtype alfa 8, til fremstilling af lægemidler til behandling af virusinfektioner i leveren DK0741577T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9404379A GB9404379D0 (en) 1994-03-07 1994-03-07 Therapeutic improvement
GB9420340A GB9420340D0 (en) 1994-10-10 1994-10-10 Therapeutic improvement
PCT/GB1995/000488 WO1995024212A1 (en) 1994-03-07 1995-03-07 The use of interferon subtypes in the preparation of medicaments to treat viral infections

Publications (1)

Publication Number Publication Date
DK0741577T3 true DK0741577T3 (da) 2003-02-17

Family

ID=26304449

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95910629T DK0741577T3 (da) 1994-03-07 1995-03-07 Anvendelsen af enterferon, subtype alfa 8, til fremstilling af lægemidler til behandling af virusinfektioner i leveren

Country Status (10)

Country Link
US (1) US6007805A (de)
EP (1) EP0741577B1 (de)
JP (1) JP4001379B2 (de)
AT (1) ATE227133T1 (de)
AU (1) AU1854695A (de)
DE (1) DE69528751T2 (de)
DK (1) DK0741577T3 (de)
ES (1) ES2186714T3 (de)
PT (1) PT741577E (de)
WO (1) WO1995024212A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563487A1 (de) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon
GB9702021D0 (en) * 1997-01-31 1997-03-19 Imperial College Medicaments
US6436391B1 (en) * 1997-01-31 2002-08-20 Imperial College Of Science, Technology & Medicine Use of interferon (IFN)-α8 and -α14 as vaccine adjuvants
IT1295657B1 (it) * 1997-11-04 1999-05-24 Alfa Wassermann Spa Oligopeptidi antiparalleli e oligopeptidi idrofobicamente complementari, matrici che li contengono e loro uso nella
ES2138565B1 (es) * 1998-05-13 2000-08-16 Inst Cientifico Tecnol Navarra Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es.
GB9818445D0 (en) * 1998-08-24 1998-10-21 Imp College Innovations Ltd Medicaments
AU2587002A (en) * 2000-11-03 2002-05-15 Biomedicines Inc Method for short-term and long-term drug dosimetry
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
IL161889A0 (en) * 2001-11-09 2005-11-20 Biomedicines Inc Method for treating diseases with omega interferon
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP4866612B2 (ja) * 2003-11-12 2012-02-01 株式会社林原生物化学研究所 生理活性複合体
NZ547157A (en) 2003-12-10 2009-07-31 Medarex Inc Interferon Alpha Antibodies and their uses
EP2327724A3 (de) 2004-02-02 2011-07-27 Ambrx, Inc. Modifizierte humane Wachstumshormon-Polypeptide und deren Verwendungen
AU2005245918A1 (en) 2004-05-19 2005-12-01 F. Hoffmann-La Roche Ag Interferon-alpha polypeptides and conjugates
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
MX2007014524A (es) 2005-05-18 2008-02-07 Maxygen Inc Polipeptidos desarrollados de interferon-alfa.
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
EP2049081B1 (de) 2006-08-09 2012-11-14 Intarcia Therapeutics, Inc. Osmotische freisetzungssysteme und kolbenanordnungen
HRP20130259T1 (hr) 2007-04-23 2013-04-30 Intarcia Therapeutics, Inc. Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
KR20110005806A (ko) 2008-03-21 2011-01-19 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 인간 인터페론 α 서브타입 α8 및 그 변이 단백질을 특이적으로 인식하는 단일클론 항체
SMT201700583T1 (it) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
GB201215873D0 (en) 2012-09-05 2012-10-24 Alfacyte Ltd Compositions and methods relating to the treatment of allergy and allergic diseases
GB201404403D0 (en) * 2014-03-12 2014-04-23 Alfacyte Ltd Compositions and methods relating to the treatment of diseases
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
CA2998456A1 (en) 2015-09-15 2017-03-23 Alfacyte Ltd Compositions and methods relating to the treatment of diseases
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH657141A5 (de) * 1980-07-01 1986-08-15 Hoffmann La Roche Dns-sequenzen, rekombinante expressionsvektoren zur mikrobiellen herstellung von human-leukozyten-interferonen und transformierte mikroorganismen.
GB8303165D0 (en) * 1983-02-04 1983-03-09 Secher D S Monoclonal antibody
JPH02197539A (ja) * 1989-01-26 1990-08-06 Tanaka Kikinzoku Kogyo Kk 装飾品用Ｃｏ含有貴金属材料
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
DE69324671D1 (de) * 1992-02-10 1999-06-02 Interferon Sciences Inc Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute

Also Published As

Publication number Publication date
DE69528751T2 (de) 2003-07-10
JP4001379B2 (ja) 2007-10-31
US6007805A (en) 1999-12-28
ES2186714T3 (es) 2003-05-16
AU1854695A (en) 1995-09-25
EP0741577A1 (de) 1996-11-13
PT741577E (pt) 2003-03-31
DE69528751D1 (de) 2002-12-12
WO1995024212A1 (en) 1995-09-14
JPH09509955A (ja) 1997-10-07
ATE227133T1 (de) 2002-11-15
EP0741577B1 (de) 2002-11-06

Similar Documents

Publication Publication Date Title
DK0741577T3 (da) Anvendelsen af enterferon, subtype alfa 8, til fremstilling af lægemidler til behandling af virusinfektioner i leveren
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
KR880010777A (ko) 바이러스 억제제와 결합한 dsRNA로 인간의 바이러스 감염을 치료하는 방법
ATE277612T1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
MY138860A (en) Hiv protease inhibitors.
ATE81978T1 (de) Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE3684363D1 (de) Phosphonylmethoxyalkyl-adeninen zur behandlung von viruskrankheiten.
BR9808100A (pt) Utilização de amandantina para tratamento de hepatite c.
ES2125976T3 (es) Otros derivados de indol con accion antiviral.
DE60237721D1 (de) Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen
DE69310528D1 (de) Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
DE60009146D1 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und ein herzglykosid enthalten
TR200102024T2 (tr) Yeni tedavi.
FR2572286B1 (fr) Utilisation du 1-b-d-ribofuranosyl-1,2,4-triazole-3-carboxamide pour le traitement de maladies virales chez l'homme
ATE193206T1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
ATE174507T1 (de) Verwendung eines benzimidazolwurmmittels zur behandlung von mikrosporeninfektionen
EP1240899A3 (de) Regulierung der TH1/TH2 Cytokinexpression durch Ribavirin and Ribavirinanaloge in activierten T-Lymphocyten, zur Behandlung der HCV-Infektionen
FI952018A0 (fi) BHAP-yhdisteiden käyttö yhdessä muiden ei-nukleosidi-käänteistransskriptaasi-inhibiittoreiden kanssa HIV-infektion hoitoon
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
EP1143981A4 (de) Behandlung und vorbeugung von hiv- und anderen virus infektionen
ATE87482T1 (de) Pharmazeutische praeparate zur behandlung von zereberalen psycho-organischen syndromen.
DK0671918T3 (da) Præparater indeholdende acyclovir-lignende forbindelser og 2-vinylsubstituerede nucleosidanaloge til behandling af virusinfektioner
ATE137968T1 (de) Verwendung von l-2-oxothiazolidine-4-carboxylate zur herstellung eines arzneimittels zur behandlung von latenten hiv-infektionen
ES8700940A1 (es) Procedimiento de obtencion de composiciones para el trata- miento de infecciones por rinovirus